drugset / Trial / NCT02269319
MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
Timeline
- Start
- 2015-02
- Primary completion
- 2015-08
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Contezolid | Small molecule | 800 mg | Oral |
| Comparator | Linezolid | Other / unclassified | 600 mg | Oral |